Silicon Therapeutics simulates biological molecules using the laws of physics in order to predict behavior and interactions of drugs and their targets. The simulation is run on an advanced computing platform named “Neo”, which is a 400+ GPU cluster paired with advanced Intel Skylake processors that is housed at the MGHPCC.
Our innovative research combines deep drug discovery experience with cutting-edge capabilities in biology, chemistry, biophysics, and simulations.
Silicon Therapeutic’s’ technology is focused on small molecule drug design, focusing on previously “undruggable” protein targets. Recent work has focused on novel cancer and autoinflammatory treatments.
Our mission is to improve the lives of patients by designing novel medicines for challenging disease targets using our proprietary physics-driven discovery engine.
P. W. Snyder, J. Mecinovicì, D. T. Moustakas, S. W. Thomas, M. Harder, E. T. Mack, M. R. Lockett, A. Heìroux, W. Sherman, G. M. Whitesides. “Mechanism of the hydrophobic effect in the biomolecular recognition of arylsulfonamides by carbonic anhydrase.” Proc Natl Acad Sci; 108 (44): 17889-17894 (2011)
G. M. Sastry, M. Adzhigirey, T. Day, R. Annabhimoju, W. Sherman. “Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments.” J Comp-Aided Mol Des; 27 (3): 221–234 (2013)
Z. Cournia, B. Allen, W. Sherman. “Relative binding free energy calculations in drug discovery: recent advances and practical considerations.” J Chem Inf Model; 57 (12): 2911–2937 (2017)
Intellectual Property (IP)
STING Agonist (Cancer) – Pre-Clinical
STING Agonist Combo (Cancer) – Pre-Clinical
Innate Immune Check-Point ADAR1 Antagonist (Cancer) – Discovery
Innate Immune Inhibitor (Autoinflammatory diseases) – Discovery
Oncogenic Phosphatase (Cancer) – Discovery
Immune Checkpoint Phosphatase (Cancer) - Discover
Progress to Date
2016: $15 Million Series A funding
2017: Dr. Chris Winter joins as Chief of R&D
2018: Preclinical data showing Systemic Small Molecule (STING) driving Tumor Regression
2019: $35 Million Series B funding
- Chengwei Capital